药品详细
Zinc(锌)
化学结构式图
中文名
锌
英文名
Zinc
分子式
Zn
化学名
zinc
分子量
Average: 65.409
Monoisotopic: 63.929146578
Monoisotopic: 63.929146578
CAS号
7440-66-6
ATC分类
D11A 未知;C05A 未知;A12C 未知;A16A Other Alimentary Tract and Metabolism Products;D09A 未知;A12C 未知;S01A 抗感染药;A12C 未知;A12C 未知;B05X 未知
药物类型
small molecule
阶段
approved
商品名
同义名
基本介绍
A metallic element of atomic number 30 and atomic weight 65.38. It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division. Zinc deficiency is associated with anemia, short stature, hypogonadism, impaired wound healing, and geophagia. It is known by the symbol Zn.
生产厂家
封装厂家
- Advanced Pharmaceutical Services Inc.
- AG Marin Pharmaceuticals
- Alaven Pharmaceutical
- American Regent
- Amneal Pharmaceuticals
- Arbor Pharmaceuticals Incorporated
- Atley Pharmaceuticals
- Auriga Pharmaceuticals LLC
- Bio Pharm Inc.
- Bradley Pharmaceuticals Inc.
- Breckenridge Pharmaceuticals
- Bristol-Myers Squibb Co.
- Cardinal Health
- Carlisle Laboratories Inc.
- Centurion Labs
- Chemins Co. Inc.
- Confab Laboratories Inc.
- Contract Pharm
- Cypress Pharmaceutical Inc.
- Dispensing Solutions
- Equipharm Inc.
- Ethex Corp.
- Everett Laboratories Inc.
- Fielding Pharmaceutical Co.
- Gate Pharmaceuticals
- Gil Pharmaceutical Corp.
- Gorbec Pharmaceutical Services Inc.
- H and H Laboratories
- Hawkeye Jensen Inc.
- Heel Inc.
- Hi Tech Pharmacal Co. Inc.
- Hillestad Pharmaceuticals Usa Inc.
- Hospira Inc.
- Hyrex Pharmaceuticals
- JLM Pharmatech
- Key Co.
- Kowa Pharmaceuticals America Inc.
- KV Pharmaceutical Co.
- Laser Pharmaceuticals
- Llorens Pharmaceutical
- Loma Lux Laboratories
- Luar Laboratories
- Luitpold Pharmaceuticals Inc.
- Major Pharmaceuticals
- Marlop Pharmaceuticals Inc.
- Marnel Pharmaceuticals Inc.
- Medecor Pharma LLC
- Midlothian Labs
- Mission Pharmacal
- Murfreesboro Pharmaceutical Nursing Supply
- Nexgen Pharma Inc.
- Novavax Inc.
- Novis PR Inc.
- Paddock Labs
- Pascal Co. Inc.
- PCA LLC
- Pecos Pharmaceutical Inc.
- Perrigo Co.
- Pharmaceutical Utilization Management Program VA Inc.
- Pharmedix
- Pharmelle LLC
- Pharmics Inc.
- Phoenix Labs Rising LLC
- Physicians Total Care Inc.
- Prepackage Specialists
- Provident Pharmaceuticals LLC
- Puretek Corp.
- Qualitest
- Remedy Repack
- Rising Pharmaceuticals
- River's Edge Pharmaceuticals
- Sagmel Inc.
- Seneca Pharmaceuticals Inc.
- Seyer Pharmatec Inc.
- Teva Pharmaceutical Industries Ltd.
- Upsher Smith Laboratories
- US Pharmaceutical Corp.
- V Sab Medical Labs Inc.
- Warner Chilcott Co. Inc.
- Wyeth Pharmaceuticals
- Xanodyne Pharmaceuticals Inc.
参考
| Synthesis Reference | Not Available |
| General Reference | Not Available |
剂型
规格
化合物类型
| Type | small molecule |
| Classes |
|
| Substructures |
|
适应症
药理
| Indication | Not Available |
| Pharmacodynamics | Not Available |
| Mechanism of action | Not Available |
| Absorption | Not Available |
| Volume of distribution | Not Available |
| Protein binding | Not Available |
| Metabolism |
Not Available
|
| Route of elimination | Not Available |
| Half life | Not Available |
| Clearance | Not Available |
| Toxicity | Not Available |
| Affected organisms | Not Available |
| Pathways | Not Available |
理化性质
| Properties | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| State | solid | |||||||||||||||||||||||||||
| Experimental Properties |
|
|||||||||||||||||||||||||||
| Predicted Properties |
|
|||||||||||||||||||||||||||
药物相互作用
| Drug | Interaction |
|---|---|
| Ciprofloxacin | Formation of non-absorbable complexes |
| Deferiprone | Deferiprone serum concentrations may be decreased by zinc salts except for zinc chloride. |
| Demeclocycline | Formation of non-absorbable complexes |
| Doxycycline | Formation of non-absorbable complexes |
| Gatifloxacin | Formation of non-absorbable complexes |
| Gemifloxacin | Formation of non-absorbable complexes |
| Grepafloxacin | Formation of non-absorbable complexes |
| Levofloxacin | Formation of non-absorbable complexes |
| Minocycline | Formation of non-absorbable complexes |
| Moxifloxacin | Formation of non-absorbable complexes |
| Norfloxacin | Formation of non-absorbable complexes |
| Ofloxacin | Formation of non-absorbable complexes |
| Tetracycline | Formation of non-absorbable complexes |
| Trovafloxacin | Zinc may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the zinc containing agent to minimize the interaction. |
食物相互作用
Not Available
收藏